(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/260111 A1

(51) International Patent Classification:
A61K 31/437 (2006.01) *A61K 39/395* (2006.01)
A61K 31/454 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4709 (2006.01) *A61P 35/00* (2006.01)
A61K 31/505 (2006.01) *A61K 31/4184* (2006.01)
A61K 31/506 (2006.01) *A61K 31/47* (2006.01)
A61K 31/517 (2006.01) *A61K 31/55* (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:
PCT/EP2021/067349

(22) International Filing Date:
24 June 2021 (24.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20182364.8 25 June 2020 (25.06.2020) EP

(71) Applicant: **TOLREMO THERAPEUTICS AG** [CH/CH]; Hofackerstrasse 40b, 4132 Muttenz (CH).

(72) Inventors: **FLÜCKIGER-MANGUAL, Stefanie**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH). **GRUBER, Dorothea**; c/o TOLREMO therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH). **BOHNACKER, Thomas**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH). **SCHWILL, Martin**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH). **SCHMITZ-ROHMER, Debora**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH). **FABRITIUS, Charles-Henry**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH). **LAUDATO, Sara**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttenz (CH).

(74) Agent: **MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH**; Dr. Andreas Ledl, Elisenhof, Elisenstrasse 3, 80335 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2021/260111 A1

(54) Title: COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND A KRAS INHIBITOR FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention is *inter alia* concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor; and (iii) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and a KRAS inhibitor.